comparemela.com

Latest Breaking News On - Therapeutic development - Page 12 : comparemela.com

Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note published on Thursday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Navidea Biopharmaceuticals stock opened at $0.04 on Thursday. The firm has a market capitalization of $4.09 million, a PE ratio of -0.68 and […]

Navidea-biopharmaceuticals-company-profile
Navidea-biopharmaceuticals-inc
Therapeutic-development-programs
Navidea-biopharmaceuticals
Free-report
Get-free-report
Street-corp
Diagnostic-substances
Therapeutic-development
Navidea-biopharmaceuticals-daily
Nyse-navb

Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.06 on Wednesday. The stock has a market capitalization of $5.75 million, a price-to-earnings ratio of -0.96 and a beta of […]

Renaissance-technologies
Navidea-biopharmaceuticals-company-profile
Therapeutic-development-programs
Allred-capital-management
Navidea-biopharmaceuticals-inc
Navidea-biopharmaceuticals
Free-report
Get-free-report
Capital-management
State-street-corp
Street-corp

Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NYSE:NAVB opened at $0.06 on Wednesday. The firm has a fifty day simple moving average of $0.06 and a two-hundred day simple […]

Renaissance-technologies
Therapeutic-development-programs
Allred-capital-management
Navidea-biopharmaceuticals-inc
Navidea-biopharmaceuticals
Free-report
Get-free-report
Capital-management
Street-corp
Diagnostic-substances
Therapeutic-development

Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note published on Wednesday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NAVB opened at $0.06 on Wednesday. Navidea Biopharmaceuticals has a one year low of $0.02 and a one year high of […]

Navidea-biopharmaceuticals-company-profile
Navidea-biopharmaceuticals-inc
Allred-capital-management
Renaissance-technologies
Therapeutic-development-programs
Navidea-biopharmaceuticals
Free-report
Get-free-report
Capital-management
Street-corp
Diagnostic-substances

Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock. Navidea Biopharmaceuticals Stock Up 8.9 % Shares of NYSE NAVB opened at $0.06 on Wednesday. The stock has a fifty day moving average price […]

Renaissance-technologies
Navidea-biopharmaceuticals-inc
Therapeutic-development-programs
Allred-capital-management
Navidea-biopharmaceuticals
Get-free-report
Capital-management
State-street-corp
Street-corp
Diagnostic-substances
Therapeutic-development

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.